Payment overview · 2025
General Payments
$1,808.68
105 reported records · 23 companies
Healthcare provider profile · identity verified
Toby M Bond, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WATKINSVILLE, GA · NPI 1467463513
Verified facts
What the public records show
CMS Open Payments records show Toby M Bond, MD received $1,808.68 in general payments during 2025 across 105 reported records.
Novo Nordisk Inc accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $416.46 | 23.0% | 20 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $294.67 | 16.3% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $249.82 | 13.8% | 23 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $127.25 | 7.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $100.83 | 5.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.06 | 4.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $78.04 | 4.3% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.36 | 4.1% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $72.07 | 4.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.05 | 2.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.50 | 1.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.42 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.36 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.25 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.93 | 1.2% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $21.65 | 1.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.23 | 1.2% | 1 | 2025 |
| Lucid Diagnostics Inc. | Unresolved — no canonical attribution shown | $20.80 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.28 | 1.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.13 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.43 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.77 | 0.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $14.32 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,808.68 | 105 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $300.72 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $182.91 | 18 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $152.92 | 9 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $152.92 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $141.75 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $141.75 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $136.96 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $127.25 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $98.43 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $92.09 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $78.06 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $78.06 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $78.04 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $73.36 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $72.07 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.60 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $56.98 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $43.85 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| AFINION 2 Normalized: afinion 2 |
Device | Abbott Laboratories | $30.42 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $17.21 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 141 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 191 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 180 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
191 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
180 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
34 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 985 | 283 |
| Levothyroxine Sodium | Levothyroxine Sodium | 795 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 686 | 212 |
| Lisinopril | Lisinopril | 600 | 179 |
| Omeprazole | Omeprazole | 478 | 138 |
| Citalopram Hbr | Citalopram Hydrobromide | 434 | 117 |
| Losartan Potassium | Losartan Potassium | 406 | 120 |
| Metformin Hcl | Metformin Hcl | 347 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 89 |
| Gabapentin | Gabapentin | 299 | 81 |
| Alendronate Sodium | Alendronate Sodium | 278 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 231 | 75 |
| Furosemide | Furosemide | 222 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 59 |
| Montelukast Sodium | Montelukast Sodium | 211 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 206 | 60 |
| Mounjaro | Tirzepatide | 191 | 30 |
| Ozempic | Semaglutide | 180 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 175 | 53 |
| Carvedilol | Carvedilol | 168 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 38 |
| Tramadol Hcl | Tramadol Hcl | 148 | 34 |
| Trazodone Hcl | Trazodone Hcl | 144 | 36 |
| Jardiance | Empagliflozin | 141 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 34 |
| Meloxicam | Meloxicam | 134 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 44 |
| Potassium Chloride | Potassium Chloride | 130 | 30 |
| Eliquis | Apixaban | 120 | 27 |
| Simvastatin | Simvastatin | 115 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 48 |
| Allopurinol | Allopurinol | 110 | 35 |
| Famotidine | Famotidine | 105 | 36 |
| Prednisone | Prednisone | 103 | 58 |
| Sertraline Hcl | Sertraline Hcl | 103 | 27 |
| Glipizide Er | Glipizide | 102 | 30 |
| Metformin Hcl Er | Metformin Hcl | 102 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 87 | 73 |
| Donepezil Hcl | Donepezil Hcl | 87 | 21 |
| Cefuroxime | Cefuroxime Axetil | 84 | 68 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 21 |
| Azithromycin | Azithromycin | 75 | 60 |
| Bupropion Xl | Bupropion Hcl | 75 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 14 |
| Spironolactone | Spironolactone | 68 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 15 |
| Xarelto | Rivaroxaban | 67 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 21 |
| Estradiol | Estradiol | 65 | 23 |
| Synthroid | Levothyroxine Sodium | 64 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 22 |
| Atenolol | Atenolol | 59 | 19 |
| Farxiga | Dapagliflozin Propanediol | 59 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 12 |
| Glipizide | Glipizide | 54 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 16 |
| Finasteride | Finasteride | 53 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 16 |
| Ezetimibe | Ezetimibe | 52 | 19 |
| Fluconazole | Fluconazole | 50 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 22 |
| Celecoxib | Celecoxib | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | 13 |
| Linzess | Linaclotide | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 26 |
| Alprazolam | Alprazolam | 40 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | 11 |
| Clonazepam | Clonazepam | 38 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | 13 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | 12 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | 14 |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 13 |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 24 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 13 |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Nucynta | Tapentadol Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,808.68 · 105 records | Novo Nordisk Inc | AFINION 2, AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, EVENITY, FANAPT, HETLIOZ, JARDIANCE, Kerendia, Korlym, Leqembi, MOUNJARO, NEFFY, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SYNTHROID, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error